RT Journal Article
SR Electronic
T1 Mass spectrometry methods for biomarker research for chronic lung allograft dysfunction (CLAD) in systems prediction of CLAD (SysCLAD)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2457
VO 44
IS Suppl 58
A1 Johanna Claustre
A1 Sébastien Quétant
A1 Candice Trocmé
A1 Sandrine Bourgoin-Voillard
A1 Hélène Flamant-Waret
A1 Izabel Bérard
A1 Bertrand Toussaint
A1 Karine Botturi-Cavaillès
A1 Antoine Magnan
A1 Laurent Nicod
A1 Christophe Pison
A1 Michel Sève
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2457.abstract
AB Background: CLAD is an irreversible and heterogeneous condition, associating Bronchiolitis Obliterans Syndrome (BOS), and Restrictive Allograft Syndrome (RAS). RAS and early onset of BOS are correlated with a poor prognosis and a significant morbidity in lung transplant recipients. As a part of SysCLAD, a FP-7 funded project aimed to predict CLAD, this study was designed to find biomarkers of CLAD in lung transplant recipients from the French cohort of lung transplant COLT and the Swiss cohort STCS, by using 2 mass spectrometry (MS) techniques.Methods: BALF and plasma in the 200 first patients of COLT cohort who reached 3 years post-transplantation or developed an early form of CLAD were selected for analysis from systematic visits at months 6 and 12. First, SELDI-TOF MS analysis, a high-throughput method, allowed obtaining individual proteomic profiles using 3 complementary arrays: CM10 (cation array), Q10 (anion array) and IMAC-Cu (copper array). Furthermore, after pooling samples according to patients' phenotype (BOS, RAS, stable), iTRAQ-MALDI-TOF MS and MS/MS analysis, a sensitive and quantitative method, allowed biomarker identification after peptide separation by off-gel fractionation and nano-reversed phase chromatography.Results: In a pilot study, 45 proteins were differentially expressed in BALF with SELDI-TOF MS analysis. Identification and quantification of these potential biomarkers is currently performed with iTRAQ analysis.Conclusion: Identification and validation of early biomarkers of CLAD with these two complementary methods may help to understand involved mechanisms and to earlier diagnose CLAD onset at a reversible stage.